BioTek Receives Transcreener® Far Red FP Certification from BellBrook Labs for Multi-Mode Microplate Readers
July 30, 2008
The patented Transcreener HTS assay platform is a universal, high throughput biochemical assay group that detects nucleotides formed by thousands of cellular enzymes, many of which catalyze the covalent regulatory reactions that are central to cell signaling and are high value targets in drug discovery applications. The Transcreener platform uses a far red shifted dye to overcome compound interference and relies on a proprietary fluorescence detection method, read using BioTek’s Synergy 2 and Synergy 4 Multi-Mode Microplate Readers, to enable an entire family of enzymes to be screened using a single set of detection reagents. No other HTS platform has the potential to eliminate costly assay development for so many drug targets to this degree.
Commenting on the certification, Bob Lowery, CEO of BellBrook Labs stated, “BellBrook’s primary goal is to accelerate the discovery of innovative new therapies for debilitating diseases, and the Transcreener Platform has already had a big impact by enabling our customers to screen a very diverse collection of promising, yet challenging targets. Making this capability broadly accessible requires straightforward implementation on the major instrument platforms, and our partnership with BioTek is a major step in this direction.”
BioTek’s patent-pending Synergy™ 4 Hybrid Microplate Reader is the first in its class to combine sensitive filter-based and flexible quadruple monochromator-based fluorescence detection technology in one compact unit. Using Hybrid Technology™, customers can now benefit from endless flexibility and true multi-detection for an unlimited number of current and future microplate-based assays. In addition, Synergy 4 includes Fluorescence Intensity, Luminescence, Fluorescence Polarization, Time-Resolved Fluorescence, and UV-Visible Absorbance.
The Synergy 2 Multi-Mode Microplate Reader incorporates modular detection modes for Fluorescence Intensity, Fluorescence Polarization, Time Resolved Fluorescence, Luminescence and UV-visible Absorbance. Synergy 2 uses a unique combination of monochromator and filter technologies as well as three broad-spectrum light sources for optimal illumination to provide the best possible level of performance in all detection modes without performance degradation.
BioTek Instruments, Inc., headquartered in Winooski, VT, is a worldwide leader in the design, manufacture, and sale of microplate instrumentation and software. BioTek instrumentation is used to accelerate the drug discovery process, to advance discoveries in genomics and proteomics, and to aid in the advancement of life science research. Founded in 1968, BioTek Instruments is celebrating its 40th anniversary this year.
Founded in 2002, BellBrook Labs provides the pharmaceutical industry with high throughput screening (HTS) tools that accelerate the discovery of effective therapies. In 2005, with the development of the Transcreener Assay Platform, BellBrook Labs introduced HTS methods that removed the assay development bottlenecks restricting access to many promising therapeutic, ADME and safety drug targets. Data generated from these assays allow better prediction about how patients will respond to drugs and improve the business case for drug target testing and the development of new drug treatments. BellBrook Labs acquired Salus Technologies in 2007 to develop a novel technology platform that enables screening labs to expand their cellular assay capabilities. By providing innovative biochemistry and cell biology technologies, BellBrook is able to answer many of the challenges faced by drug discovery.
Transcreener HTS Assay Platform is a patented technology of BellBrook Labs.
Transcreener is a registered trademark of BellBrook Labs.
For further information, contact:
Xavier Amouretti, Product Manager
BioTek Instruments, Inc.
Chere Griffin, Account Executive
Shaw & Todd Advertising and Marketing Communications